Search Results - "Betz, Margaux"
-
1
Validation of the Idylla GeneFusion assay to detect fusions and MET exon-skipping in non-small cell lung cancers
Published in Scientific reports (09-08-2023)“…Gene fusions and MET exon skipping drive oncogenesis in 8–9% and 3% of non-small cell lung cancers (NSCLC) respectively. Their detection are essential for the…”
Get full text
Journal Article -
2
DDB2 represses epithelial-to-mesenchymal transition and sensitizes pancreatic ductal adenocarcinoma cells to chemotherapy
Published in Frontiers in oncology (08-12-2022)“…Damage specific DNA binding protein 2 (DDB2) is an UV-indiced DNA damage recognition factor and regulator of cancer development and progression. DDB2 has dual…”
Get full text
Journal Article -
3
DDB2 expression lights the way for precision radiotherapy response in PDAC cells, with or without olaparib
Published in Cell death discovery (27-09-2024)“…Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers. Therapeutic options for PDAC are primarily restricted to surgery in the early stages…”
Get full text
Journal Article -
4
IESR1/I Gene Mutations and Liquid Biopsy in ER-Positive Breast Cancers: A Small Step Forward, a Giant Leap for Personalization of Endocrine Therapy?
Published in Cancers (01-10-2023)“…Endocrine therapy (ET) remains the mainstay of treatment for Hormone Receptor-positive breast cancer, both in the early and advanced settings. The acquisition…”
Get full text
Journal Article -
5
Tumor-derived cell-free DNA and circulating tumor cells: partners or rivals in metastasis formation?
Published in Clinical and experimental medicine (17-01-2024)“…The origin of metastases is a topic that has sparked controversy. Despite recent advancements, metastatic disease continues to pose challenges. The first…”
Get full text
Journal Article -
6
ESR1 Gene Mutations and Liquid Biopsy in ER-Positive Breast Cancers: A Small Step Forward, a Giant Leap for Personalization of Endocrine Therapy?
Published in Cancers (27-10-2023)“…The predominant forms of breast cancer (BC) are hormone receptor-positive (HR+) tumors characterized by the expression of estrogen receptors (ERs) and/or…”
Get full text
Journal Article